Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Extoxnet (extension toxicology network), 4-aminopyridine
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Disease-modifying treatments for progressive multiple sclerosis.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Copolymer 1 inhibits manifestations of graft rejection.
Ustekinumab.
Rituximab Use in Pediatric Central Demyelinating Disease.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Roche reports positive studies of MabThera given by subcutaneous injection
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
[Nicolau syndrome after administration of glatiramer acetate].
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.

Pages